News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Month Year

Feb 3, 2021

Astellas' XOSPATA® (gilteritinib) Receives Conditional Approval by China's National Medical Products Administration for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

- Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings
Jan 28, 2021

Astellas Achieves 100% Score on Corporate Equality Index for Seventh Consecutive Year
Jan 6, 2021

FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients
Dec 21, 2020

Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Dec 14, 2020

Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise
Nov 27, 2020

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis
Nov 16, 2020

Astellas to Present New Data on Gilteritinib in FLT3 Mutation-Positive Acute Myeloid Leukemia at the 2020 American Society of Hematology Annual Meeting

Includes five oral presentations that collectively explore the use of gilteritinib across the FLT3mut+ AML care continuum
Nov 6, 2020

XTANDI® (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

Enzalutamide is now NMPA-approved for both non-metastatic and metastatic castration-resistant prostate cancer
Oct 28, 2020

Astellas Receives U.S. FDA Fast Track Designation for ASP5354, an Investigational Near-Infrared Fluorescence Imaging Agent
- Photos 1
Oct 20, 2020

U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa